Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, John B Haanen, Christian U Blank, Maureen J B Aarts, Franchette W P J van den Berkmortel, Jan-Willem B de Groot, Geke A P Hospers, Ellen Kapiteijn, Djura Piersma, Roos S van Rijn, Karijn P M Suijkerbuijk, Willeke A M Blokx, Bert-Jan J Ten Tije, Astrid A M van der Veldt, Art Vreugdenhil, Marye J Boers-Sonderen, Alfonsus J M van den Eertwegh

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Abstract

Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021

Original languageEnglish
Article number1746
Number of pages1
JournalBritish Journal of Cancer
Volume124
Issue number10
Early online date15 Mar 2021
DOIs
Publication statusPublished - 11 May 2021

Fingerprint

Dive into the research topics of 'Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis'. Together they form a unique fingerprint.

Cite this